Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
Mais filtros

Medicinas Complementares
Tipo de documento
Intervalo de ano de publicação
1.
Nutr Clin Pract ; 39(2): 356-365, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38030578

RESUMO

High-dose vitamin B12 is a potential treatment for patients with vasodilatory shock that is refractory to other therapies. Vasodilatory shock is characterized by low blood pressure and low systemic vascular resistance. Nitric oxide and hydrogen sulfide, two potential targets of high-dose vitamin B12 given as hydroxocobalamin, facilitate this syndrome. This review explores the relationship between high-dose vitamin B12 and hemodynamic outcomes in adults with vasodilatory shock and provides an update on the literature since a 2019 review on this topic. A literature search of studies published in the past 5 years was conducted in the CINAHL, PubMed, Cochrane, and EMBASE databases in May 2023. After assessing for eligibility, eight studies met this review's inclusion criteria. Seven of the eight studies reported decreased vasopressor requirements for part or all of the study samples after receiving a hydroxocobalamin infusion. However, not all patients responded to hydroxocobalamin. These findings are limited by patient selection and differences in the timing of vasopressor requirement and blood pressure outcome assessments. The current evidence is promising as to whether vitamin B12 , given as a hydroxocobalamin infusion, may improve hemodynamic outcomes in vasodilatory shock, but the evidence is of low quality. The use of hydroxocobalamin to treat refractory, vasodilatory shock remains investigative. Larger randomized controlled trials are required to elucidate the role of vitamin B12 in treating refractory, vasodilatory shock, including in conjunction with other alternative therapies such as methylene blue and corticosteroids.


Assuntos
Choque , Vitamina B 12 , Adulto , Humanos , Vitamina B 12/uso terapêutico , Hidroxocobalamina/uso terapêutico , Choque/tratamento farmacológico , Vasoconstritores/uso terapêutico , Vitaminas/uso terapêutico
2.
Chin J Integr Med ; 29(12): 1142-1146, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37222829

RESUMO

Shock is the clinical manifestation of acute circulatory failure, which results in inadequate utilization of cellular oxygen. It is a common condition with high mortality rates in intensive care units. The intravenous administration of Shenfu Injection (SFI) may attenuate inflammation, regulate hemodynamics and oxygen metabolism; inhibit ischemia-reperfusion responses; and have adaptogenic and antiapoptotic effects. In this review, we have discussed the clinical applications and antishock pharmacological effects of SFI. Further in-depth and large-scale multicenter clinical studies are warranted to determine the therapeutic effects of SFI on shock.


Assuntos
Medicamentos de Ervas Chinesas , Choque , Humanos , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Choque/tratamento farmacológico , Injeções , Oxigênio , Estudos Multicêntricos como Assunto
3.
Am J Med Sci ; 365(4): 396-400, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36535540

RESUMO

Differentiating the type and cause of shock is crucial for intensive care. The rapid aggravation of lactic acidosis in patients often indicates a severe impairment of oxygen uptake in tissues. Herein, we presented a rare case of refractory distributive shock with severe wet beriberi. A 40-year-old male was admitted to the emergency department (ED) with recurrent chest tightness and lower extremity edema. The condition of the patient continued to deteriorate after symptomatic treatments. After several turnovers, the medical history of the patient was requested again and finally obtained. Our emergency management team hypothesized that the thiamine-deficient diet caused an aerobic metabolism disorder in the patient. Overall, we aimed to alert clinicians to unusual causes of distributive shock and further discussed the application of thiamine supplementary therapy in critical care.


Assuntos
Beriberi , Choque , Deficiência de Tiamina , Masculino , Humanos , Adulto , Beriberi/complicações , Beriberi/tratamento farmacológico , Tiamina/uso terapêutico , Choque/tratamento farmacológico , Choque/etiologia
4.
Cardiovasc Toxicol ; 22(1): 63-66, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34643856

RESUMO

Intoxication from calcium channel blockers exhibits almost 50% mortality rates. Amlodipine is a long-acting dihydropyridine and inappropriate dosage poses a great threat for profound vasodilation, hypotension, and refractory vasopressor-resistant shock. A 72-year-old woman with unremarkable medical history presented to the emergency department due to amlodipine overdose after a suicide attempt attributed to COVID-19 pandemic severe anxiety disorder. Vital signs at presentation: heart rate 82 beats/ min, arterial pressure 72/55 mmHg, and oxygen saturation 98%. Resuscitation was initiated with intravenous infusion of normal saline 0,9%, noradrenaline, and calcium chloride, while activated charcoal was orally administrated; however, blood pressure remained at 70/45 mmHg. Abruptly, she experienced acute pulmonary edema and was finally intubated. We commenced high-dose insulin infusion with Dextrose 10% infusion to maintain euglycemic hyperinsulinemia. Hemodynamic improvement occurred after 30 min, systolic blood pressure raised to 95 mmHg, and decongestion was achieved with intravenous furosemide. Insulin effect was dose-dependent and patient's hemodynamic status improved after insulin uptitration. Eight days later, the patient was weaned from the mechanical ventilation and she was successfully discharged after 14 days. High-dose intravenous infusion of insulin up to 10 units/kg per hour appears as an inotropic agent possibly through alterations in myocardial metabolism of fatty acids and augmentation of insulin secretion and uptake. This regimen possibly exhibits additional vasotropic properties. We conclude that euglycemic hyperinsulinemia is a potentially advantageous treatment in CCB toxicity.


Assuntos
Anlodipino/toxicidade , COVID-19 , Overdose de Drogas/tratamento farmacológico , Hiperinsulinismo/induzido quimicamente , Choque/tratamento farmacológico , Tentativa de Suicídio , Idoso , COVID-19/psicologia , Bloqueadores dos Canais de Cálcio/toxicidade , Overdose de Drogas/sangue , Overdose de Drogas/diagnóstico , Feminino , Humanos , Hiperinsulinismo/sangue , Insulina/administração & dosagem , Choque/sangue , Choque/diagnóstico , Tentativa de Suicídio/psicologia
5.
J Med Toxicol ; 17(1): 1-9, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32656625

RESUMO

INTRODUCTION: While emergency department (ED) visits for acute drug overdose are at an all-time high, the importance of vasopressors to treat circulatory shock in this patient population remains unclear. This study investigated the association between first-line vasopressor and mortality, for both push-dose and infusion, in this patient population. METHODS: From a prospective cohort of consecutive ED patients with drug overdose at two urban teaching centers over 5 years, we performed a secondary data analysis of patients with circulatory shock, defined as hypotension requiring either vasopressors, high-dose insulin euglycemia therapy, or both. The first-line vasopressor (push-dose and infusion) was analyzed for associations with the primary outcome (in-hospital mortality) and secondary outcomes (24-hour mortality, ICU LOS). Subgroup analysis of beta-/calcium-channel blocker overdose was performed to evaluate impact of antidotal therapies. Data analysis included multivariable regression. RESULTS: Fifty-five patients with circulatory shock were analyzed, in whom there was 20% 24-hour mortality, 42% in-hospital mortality, 730-minute mean vasopressor duration, and 53.4-hour median ICU LOS. On multivariable analysis, there was significantly decreased adjusted odds of in-hospital mortality with first-line push-dose phenylephrine (aOR 0.06, CI 0.01-0.55), and significantly increased adjusted odds of in-hospital mortality with first-line push-dose epinephrine (aOR 60.8, CI 6.1-608). Of the first-line infusions, norepinephrine had the lowest odds of in-hospital mortality (aOR 0.80, CI 0.2-3.1). CONCLUSIONS: In ED patients with undifferentiated drug overdose and circulatory shock, the first-line vasopressor is associated with in-hospital mortality. First-line push-dose phenylephrine was associated with the lowest odds of in-hospital mortality. Future randomized studies are warranted for validation.


Assuntos
Overdose de Drogas/tratamento farmacológico , Serviço Hospitalar de Emergência , Hemodinâmica/efeitos dos fármacos , Choque/tratamento farmacológico , Vasoconstritores/administração & dosagem , Adulto , Biomarcadores/sangue , Glicemia/efeitos dos fármacos , Glicemia/metabolismo , Overdose de Drogas/diagnóstico , Overdose de Drogas/mortalidade , Overdose de Drogas/fisiopatologia , Feminino , Mortalidade Hospitalar , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Cidade de Nova Iorque , Estudos Prospectivos , Choque/diagnóstico , Choque/mortalidade , Choque/fisiopatologia , Fatores de Tempo , Resultado do Tratamento
6.
Medicine (Baltimore) ; 99(43): e22872, 2020 Oct 23.
Artigo em Inglês | MEDLINE | ID: mdl-33120828

RESUMO

BACKGROUND: Shock is a major public health problem worldwide. At present, the morbidity and mortality of shock patients are relatively high. Vasomotor dysfunction is 1 of the key pathological aspects of shock. Shenfu injection has been widely used for the treatment of shock in China. Pharmacological studies have suggested that Shenfu injection can reduce peripheral circulation resistance and improve microcirculation. The purpose of this study is to evaluate the effect and safety of Shenfu injection on the microcirculation of patients with shock. METHODS: This review summarizes and meta-analyzes randomized controlled trials of Shenfu injection for the treatment of shock.Searched the following electronic databases: PubMed, Cochrane Library, Embase, CNKI, VIP and Wanfang Data. The Cochrane risk assessment tool was used to evaluate the methodological quality of randomized controlled trials. All tests are analyzed according to the standards of the Cochrane Handbook. Review Manager 5.3, R-3.5.1 software and Grading of Recommendations Assessment, Development, and Evaluation pro GDT web solution are used for data synthesis and analysis. RESULTS: This review focuses on the effects of Shenfu injection on the microcirculation of shock patients (blood lactic acid level, arteriovenous oxygen saturation, arteriovenous carbon dioxide partial pressure difference, sublingual microcirculation), 28-day mortality, 28-day ICU hospitalization and adverse reaction rate. CONCLUSION: This review provides a clear basis for evaluating the impact of Shenfu injection on the microcirculation of shock patients, as well as the effectiveness and safety of the treatment.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Microcirculação/efeitos dos fármacos , Choque/tratamento farmacológico , Estudos de Casos e Controles , China/epidemiologia , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/efeitos adversos , Feminino , Hospitalização/tendências , Humanos , Injeções/métodos , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Placebos/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Segurança , Choque/mortalidade , Resultado do Tratamento , Metanálise como Assunto
7.
Eur J Clin Pharmacol ; 76(7): 979-989, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32270213

RESUMO

PURPOSE: Heart failure is among the leading causes for hospitalization in Europe. In this study, we evaluate potential precipitating factors for hospitalization for heart failure and shock. METHODS: Using Swiss claims data (2014-2015), we evaluated the association between hospitalization for heart failure and shock, and prescription of oral potassium supplements, non-steroidal anti-inflammatory drugs (NSAIDs), and amoxicillin/clavulanic acid. We conducted case-crossover analyses, where exposure was compared for the hazard period and the primary control period (e.g., 1-30 days before hospitalization vs. 31-60 days, respectively). Conditional logistic regression was applied and subsequently adjusted for addressing potential confounding by disease progression. Sensitivity analyses were conducted and stratification for co-medication was performed. RESULTS: We identified 2185 patients hospitalized with heart failure or shock. Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid was significantly associated with an increased risk for hospitalization for heart failure and shock with crude odds ratios (OR) of 2.04 for potassium (95% CI 1.24-3.36, p = 0.005, 30 days), OR 1.8 for NSAIDs (95% CI 1.39-2.33, p < 0.0001, 30 days), and OR 3.25 for amoxicillin/clavulanic acid (95% CI 2.06-5.14, p < 0.0001, 15 days), respectively. Adjustment attenuated odds ratios, while the significant positive association remained (potassium OR 1.70 (95% CI 1.01-2.86, p = 0.046), NSAIDs OR 1.50 (95% CI 1.14-1.97, p = 0.003), and amoxicillin/clavulanic acid OR 2.26 (95% CI 1.41-3.62, p = 0.001). CONCLUSION: Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid is associated with increased risk for hospitalization. Underlying conditions such as pain, electrolyte imbalances, and infections are likely contributing risk factors. Physicians may use this knowledge to better identify patients at risk and adapt patient management.


Assuntos
Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Hospitalização/estatística & dados numéricos , Potássio/uso terapêutico , Choque/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Estudos Cross-Over , Uso de Medicamentos , Feminino , Insuficiência Cardíaca/epidemiologia , Humanos , Seguro Saúde , Masculino , Fatores de Risco , Choque/epidemiologia , Suíça/epidemiologia
8.
Clin Nutr ; 39(2): 460-467, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-30808573

RESUMO

BACKGROUND & AIMS: Despite extensive research on early enteral nutrition (EEN), it remains unclear whether EEN is effective for patients with shock requiring vasopressors. This study aimed to compare outcomes between EEN and late enteral nutrition (LEN) in ventilated patients with shock requiring low-, medium-, or high-dose noradrenaline. METHODS: Using a national inpatient database in Japan, we identified ventilated patients admitted to intensive care units who had shock requiring catecholamines (noradrenaline or dobutamine) from July 2010 to March 2016. We defined patients who started enteral nutrition within 2 days after starting mechanical ventilation as EEN group and the others as LEN group. Propensity score matching was performed between patients undergoing EEN and LEN in each of the low- (<0.1 µg/kg/min), medium- (0.1-0.3 µg/kg/min), and high-dose (≥0.3 µg/kg/min) noradrenaline groups. RESULTS: We identified 52,563 eligible patients during the 69-month study period, including 38,488, 11,042, and 3033 patients in the low-, medium-, and high-dose noradrenaline groups, respectively. One-to-two propensity score matching created 5,969, 2,162, and 477 one-to-two matched pairs in the low-, medium-, and high-dose noradrenaline groups, respectively. The 28-day mortality rate was significantly lower in the EEN than LEN group in the low-dose noradrenaline group (risk difference, -2.9%; 95% confidence interval [CI], -4.5% to -1.3%) and in the medium-dose noradrenaline group (risk difference, -6.8%; 95% CI, -9.6% to -4.0%). In the high-dose noradrenaline group, 28-day mortality did not differ significantly between the EEN and LEN groups (absolute risk difference, -1.4%; 95% CI, -7.4%-4.7%). CONCLUSIONS: Although the size of the subgroup requiring high-dose noradrenaline may have been too small to demonstrate a significant difference, the results suggest that EEN was associated with a reduction in mortality in ventilated adults treated with low- or medium-dose noradrenaline but not in those requiring high-dose noradrenaline.


Assuntos
Nutrição Enteral/métodos , Norepinefrina/uso terapêutico , Respiração Artificial/métodos , Choque/mortalidade , Choque/terapia , Vasoconstritores/uso terapêutico , Idoso , Bases de Dados Factuais , Relação Dose-Resposta a Droga , Feminino , Humanos , Japão/epidemiologia , Masculino , Pontuação de Propensão , Choque/tratamento farmacológico
9.
Arq Bras Cir Dig ; 32(3): e1451, 2019.
Artigo em Inglês, Português | MEDLINE | ID: mdl-31644671

RESUMO

BACKGROUND: Hypovolemic shock is a common disease in polytrauma patients and may develop ischemia in various organs, increasing morbidity and mortality. The bowel is usually most affected by this condition. AIM: To evaluate the effects of copaiba oil on the intestinal mucosa's injury of rats submitted to hypovolemic shock. METHOD: Fifteen rats were divided into three groups: sham - simulated surgery; ischemia - animals submitted to hypovolemic shock; and copaiba - animals submitted to hypovolemic shock previously treated with copaiba oil. Mean blood pressure, arterial blood gas after shock induction, degree of intestinal lesion and villus length were evaluated. RESULTS: The sham presented the lowest values of lactate and PaCO2 and the highest values of mean arterial pressure, pH and bicarbonate in relation to the other groups. The degree of mesenteric lesion was zero in the sham group; 3.00±1.00 in the ischemia group; and 3.00±0.71 in the copaiba group. The villus length was 173.60±8.42 in the sham, 142.77±8.33 in the ischemia and 143.01±9.57 in the copaiba group. There was a significant difference between the sham and the other groups (p<0.05); however, there not significant difference between groups Ischemia and copaiba. CONCLUSION: Administration of copaiba oil did not reduce the intestinal mucosa lesion of rats after hypovolemic shock.


Assuntos
Anti-Inflamatórios/farmacologia , Fabaceae/química , Mucosa Intestinal/efeitos dos fármacos , Óleos de Plantas/farmacologia , Choque , Animais , Anti-Inflamatórios/química , Anti-Inflamatórios/uso terapêutico , Modelos Animais de Doenças , Íleo/patologia , Mucosa Intestinal/patologia , Isquemia/tratamento farmacológico , Masculino , Óleos de Plantas/química , Óleos de Plantas/uso terapêutico , Distribuição Aleatória , Ratos Wistar , Choque/tratamento farmacológico
10.
Curr Pharm Des ; 25(19): 2133-2139, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31272348

RESUMO

Vasodilatory shock is a life-threatening syndrome in critically ill patients and is characterized by severe hypotension and resultant tissue hypoperfusion. This shock state requires the use of vasopressor agents to restore adequate vascular tone. Norepinephrine is still recommended as first-line vasopressor in the management of critically ill patients suffering from severe vasodilation. In the recent time, catecholaminergic vasopressor drugs have been associated with possible side effects at higher dosages. This so-called catecholamine toxicity has focused on alternative noncatecholaminergic vasopressors or the use of moderate doses of multiple vasopressors with complementary mechanisms of action. Besides vasopressin and terlipressin, angiotensin II may be a promising drug for the management of vasodilatory shock. In addition, adjunctive drugs, such as hydrocortisone, methylene blue or ascorbic acid can be added to conventional vasopressor therapy. The objective of this review is to give an overview of the current available vasopressor agents used in vasodilatory shock. A thorough search of PubMed was conducted in order to identify the majority of studies related to the subject. Data on the outcome of several drugs and future perspective of possible management strategies for the therapy of vasodilatory shock are discussed.


Assuntos
Choque/tratamento farmacológico , Vasoconstritores/uso terapêutico , Angiotensina II/uso terapêutico , Catecolaminas/efeitos adversos , Catecolaminas/uso terapêutico , Humanos , Norepinefrina/uso terapêutico , Terlipressina/uso terapêutico , Vasodilatação , Vasopressinas/uso terapêutico
11.
PLoS One ; 14(3): e0213491, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30897096

RESUMO

INTRODUCTION: Nigeria has one of the highest maternal mortality ratios in the world. The nurses and midwives being the first point of contact play a central role in addressing these problems. This study was conducted to assess the knowledge and utilization of the technologies (misoprostol, anti-shock garment and magnesium sulphate) in the reduction of maternal mortality amongst the Primary Health Care (PHC) nurses and midwives in Lagos State, Nigeria. In addition, the availability of the technologies in the flagship Primary Health Centres (PHCs) was assessed. METHODS: This was a cross-sectional study among all the nurses and midwives at the flagship PHCs in Lagos state and a total of 230 were eventually studied. Data was collected using a self-administered, structured questionnaire and a checklist. Descriptive and inferential statistics were applied. Level of significance was set at 5% (p<0.05). RESULTS: All the respondents were aware of the technologies but most (73.9%) had poor knowledge of them. Majority (74.8%) of the respondents had good knowledge of maternal mortality and its major causes. Most, 81.3% of the respondents have administered misoprostol, 37.0% magnesium sulphate while 52.2% have administered anti shock garment. Out of the 57 flagship PHCs, 27 (47.4%) had magnesium sulphate, 42 (73.7%) had misoprostol and 52 (91.2%) had anti-shock garments in their facilities. Respondents who were double qualified (nurse/midwife) had significantly better knowledge of maternal mortality and its major causes (p = 0.009) than the other cadres. Longer years of experience (p = 0.019), training in the use of misoprostol (p = 0.020) and training in the use of magnesium sulphate (p = 0.001) significantly improved knowledge of the technologies. CONCLUSION: Respondents had good knowledge of maternal mortality and its major causes and poor knowledge of the technologies for maternal mortality reduction, despite the trainings attended. Of the three technologies considered, misoprostol was the most commonly used. Periodic refresher courses for the training and retraining of PHC nurses and midwives on the technologies for maternal mortality reduction is recommended.


Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Sulfato de Magnésio/administração & dosagem , Mortalidade Materna , Misoprostol/administração & dosagem , Atenção Primária à Saúde , Choque , Inquéritos e Questionários , Adulto , Idoso , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tocologia , Nigéria/epidemiologia , Enfermeiros Obstétricos , Gravidez , Choque/tratamento farmacológico , Choque/mortalidade
13.
ABCD (São Paulo, Impr.) ; 32(3): e1451, 2019. tab
Artigo em Inglês | LILACS | ID: biblio-1038028

RESUMO

ABSTRACT Background: Hypovolemic shock is a common disease in polytrauma patients and may develop ischemia in various organs, increasing morbidity and mortality. The bowel is usually most affected by this condition. Aim: To evaluate the effects of copaiba oil on the intestinal mucosa's injury of rats submitted to hypovolemic shock. Method: Fifteen rats were divided into three groups: sham - simulated surgery; ischemia - animals submitted to hypovolemic shock; and copaiba - animals submitted to hypovolemic shock previously treated with copaiba oil. Mean blood pressure, arterial blood gas after shock induction, degree of intestinal lesion and villus length were evaluated. Results: The sham presented the lowest values of lactate and PaCO2 and the highest values of mean arterial pressure, pH and bicarbonate in relation to the other groups. The degree of mesenteric lesion was zero in the sham group; 3.00±1.00 in the ischemia group; and 3.00±0.71 in the copaiba group. The villus length was 173.60±8.42 in the sham, 142.77±8.33 in the ischemia and 143.01±9.57 in the copaiba group. There was a significant difference between the sham and the other groups (p<0.05); however, there not significant difference between groups Ischemia and copaiba. Conclusion: Administration of copaiba oil did not reduce the intestinal mucosa lesion of rats after hypovolemic shock.


RESUMO Racional: O choque hipovolêmico é situação comum em pacientes politraumatizados, podendo acarretar isquemia de vários órgãos, aumentando a morbimortalidade. O intestino é geralmente um dos órgãos mais afetados por essa condição. Objetivo: Avaliar os efeitos do óleo de copaíba na lesão da mucosa intestinal de ratos submetidos ao choque hipovolêmico. Métodos: Quinze ratos foram distribuídos em três grupos: Sham - operação simulada; isquemia - submissão ao choque hipovolêmico; e copaíba - submissão ao choque hipovolêmico previamente tratados com óleo de copaíba. A pressão arterial média, a gasometria arterial após a indução do choque, o grau da lesão intestinal e o tamanho das vilosidades foram avaliados. Resultados: O grupo sham apresentou os menores valores de lactato e PaCO2 e os maiores valores de pressão arterial média, pH e bicarbonato em relação aos demais grupos. O grau de lesão mesentérica foi de zero no sham; 3,0±1,00 no grupo isquemia; e 3,0±0,71 no da copaíba. O comprimento dos vilos foi de 173,60±8,42 no grupo sham, 142,77±8,33 no da isquemia e 143,01±9,57 no da copaíba. Houve diferença significante entre o grupo sham e os demais grupos (p<0.05); contudo, não houve diferença estatística entre os grupos submetidos ao choque hipovolêmico. Conclusão: A administração do óleo de copaíba não reduziu a lesão da mucosa intestinal de ratos submetidos ao choque hipovolêmico.


Assuntos
Animais , Masculino , Choque/tratamento farmacológico , Óleos de Plantas/farmacologia , Mucosa Intestinal/efeitos dos fármacos , Fabaceae/química , Anti-Inflamatórios/farmacologia , Óleos de Plantas/uso terapêutico , Óleos de Plantas/química , Distribuição Aleatória , Ratos Wistar , Modelos Animais de Doenças , Íleo/patologia , Mucosa Intestinal/patologia , Isquemia/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios/química
14.
Medicine (Baltimore) ; 97(15): e0479, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29642222

RESUMO

RATIONALE: Venous thromboembolism may result from prolong immobilization following intracerebral hemorrhage. Massive pulmonary embolism with associated right heart failure is life-threatening, requiring treatment with anticoagulants or even thrombolytic agents. However, these drugs are contraindicated after a recent hemorrhagic episode, as they may induce further hemorrhage. There are no guidelines for treatment in these circumstances. PATIENT CONCERNS: A 57-year-old man experienced massive pulmonary embolism and shock 18 days after an intracerebral hemorrhage. DIAGNOSES: Tachycardia and high D-dimer (21.27 mg/L fibrinogen-equivalent units) were noted. Chest computed tomography showed bilateral pulmonary trunk embolism. INTERVENTIONS: Heparinization were used and activated partial thromboplastin time therapeutic range was 50 to 70 seconds. Fortunately, shock status and shortness of breath improved two days later. Continuing high dose Rivaroxaban was administrated for three weeks. OUTCOMES: There was no recurrent intracranial hemorrhage (ICH) following treatment for three-weeks with high-dose and one-year with standard dose of rivaroxaban. This report presents a treatment option in the management of these difficult clinical situations. LESSONS: The combination of unfractionated heparin infusion and continuing non-Vitamin K antagonist oral anticoagulants use could manage life-threatening pulmonary embolism following recent ICH. Theoretically, the use of NOAC is a safer strategy if the patient with previous history of major ICH.


Assuntos
Hemorragias Intracranianas/complicações , Hemorragias Intracranianas/terapia , Embolia Pulmonar/etiologia , Embolia Pulmonar/terapia , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Heparina/uso terapêutico , Humanos , Hemorragias Intracranianas/sangue , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar/sangue , Embolia Pulmonar/tratamento farmacológico , Rivaroxabana/uso terapêutico , Choque/sangue , Choque/tratamento farmacológico , Choque/etiologia , Choque/terapia , Taquicardia/sangue , Taquicardia/tratamento farmacológico , Taquicardia/etiologia , Taquicardia/terapia , Tomografia Computadorizada por Raios X
15.
Clin Exp Pharmacol Physiol ; 45(2): 155-165, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-28949404

RESUMO

Spleen tyrosine kinase (Syk), a non-receptor tyrosine kinase, plays an important role in allergic diseases and inflammation. Syk triggers several intracellular signalling cascades including Toll-like receptor signalling to activate inflammatory responses following fungal infection but the role of this enzyme in zymosan (ZYM)-induced non-septic shock and its impacts on hypotension and inflammation in rats is not well understood. This study was conducted to determine the effects of Syk inhibition on ZYM-induced alterations in the expression and/or activities of Syk, inhibitor ĸB (IĸB)-α, and nuclear factor-ĸB (NF-ĸB) p65. We also examined the effect of Syk inhibition on inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and tumour necrosis factor (TNF)-α, and activity of myeloperoxidase (MPO) that contribute to hypotension and inflammation. Administration of ZYM (500 mg/kg, ip) to male Wistar rats decreased blood pressure and increased heart rate. These changes were associated with increased expression and/or activities of Syk, NF-κB p65, iNOS and COX-2 and decreased expression of IκB-α with enhanced levels of nitrite, nitrotyrosine, 6-keto-PGF1α , and TNF-α and activity of MPO in renal, cardiac and vascular tissues. ZYM administration also elevated serum and tissue nitrite levels. The selective Syk inhibitor BAY 61-3606 (3 mg/kg, ip) given 1 hour after ZYM injection reversed all of these changes induced by ZYM. These results suggest that Syk/IĸB-α/NF-ĸB pathway activation contributes to hypotension and inflammation caused by the production of vasodilator and proinflammatory mediators in the zymosan-induced non-septic shock model.


Assuntos
Quinase I-kappa B/metabolismo , NF-kappa B/metabolismo , Niacinamida/análogos & derivados , Pirimidinas/uso terapêutico , Choque/induzido quimicamente , Quinase Syk/metabolismo , Animais , Regulação da Expressão Gênica/efeitos dos fármacos , Quinase I-kappa B/genética , Masculino , NF-kappa B/genética , Niacinamida/uso terapêutico , Ratos , Ratos Wistar , Choque/tratamento farmacológico , Quinase Syk/antagonistas & inibidores , Quinase Syk/genética , Zimosan/toxicidade
16.
Lakartidningen ; 1142017 10 09.
Artigo em Sueco | MEDLINE | ID: mdl-28994852

RESUMO

High dose insulin euglycemia therapy - an important addition to the treatment arsenal in severe toxic myocardial depression Fifty-nine patients who developed hemodynamic symptoms necessitating treatment with vasopressors or inotropes after poisoning with calcium channel blockers (CCB) and beta blockers (BB) between January 2010 and August 2016 were identified by a search of the Poisons Information Centre database. In-hospital circulatory arrest occurred in 16/59 (27 %) and the mortality rate was 7/59 (12 %). Two cases of analytically confirmed combined BB and CCB poisoning were treated with high dose insulin therapy (HIE) and are presented in detail. The outcome in both cases was good. They were the only cases in the study population treated with HIE, although signs of cardiac dysfunction was present in 55/59 (93%) and in all cases of circulatory arrest. Animal studies and international clinical cases indicate that HIE is a safe and effective method to improve cardiac function in CCB and BB poisoning, and its implementation in Sweden may improve the outcome for this at risk population.


Assuntos
Antagonistas Adrenérgicos beta/intoxicação , Bloqueadores dos Canais de Cálcio/intoxicação , Glucose , Insulina , Choque , Feminino , Glucose/administração & dosagem , Glucose/uso terapêutico , Humanos , Insulina/administração & dosagem , Insulina/uso terapêutico , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Choque/induzido quimicamente , Choque/tratamento farmacológico
17.
Int Immunopharmacol ; 48: 159-168, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28511114

RESUMO

Bergapten (BG) is a cumarine-derivate compound in many medicinal plants. Here, in vitro and in vivo experimental results indicated that BG possesses anti-inflammatory properties, Based on this, we further investigated the precise molecular mechanisms of BG in LPS-stimulated inflammation response. Studies revealed that BG inhibited LPS-stimulated productions of TNF-α, IL-1ß, IL-6, PGE2 and NO as well as the expression of iNOS and COX-2, and at the same time, it increased LPS-induced release of IL-10 in a dose-dependent manner in RAW264.7 cells. Mechanistically, BG suppressed the activations of JAK/STAT, but not that of MAPKs and NF-κB. In addition, BG, as an antioxidant, prevented the accumulation of ROS, which further exerted its anti-inflammatory function. In vivo researches revealed that BG decreased LPS-induced mortality in mice. In conclusions, BG may be a potential candidate for inflammation therapy via inhibiting JAK/STAT activation and ROS production in RAW264.7 cells.


Assuntos
Anti-Inflamatórios/farmacologia , Metoxaleno/análogos & derivados , 5-Metoxipsoraleno , Animais , Anti-Inflamatórios/uso terapêutico , Sobrevivência Celular/efeitos dos fármacos , Ciclo-Oxigenase 2/metabolismo , Citocinas/metabolismo , Janus Quinase 1/metabolismo , Janus Quinase 2/metabolismo , Lipopolissacarídeos , Masculino , Metoxaleno/farmacologia , Metoxaleno/uso terapêutico , Camundongos , Camundongos Endogâmicos ICR , Óxido Nítrico Sintase Tipo II/metabolismo , Células RAW 264.7 , Espécies Reativas de Oxigênio/metabolismo , Fator de Transcrição STAT1/metabolismo , Fator de Transcrição STAT3/metabolismo , Choque/tratamento farmacológico
18.
Br J Clin Pharmacol ; 81(3): 453-61, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26344579

RESUMO

Management of cardiovascular instability resulting from calcium channel antagonist (CCB) or beta-adrenergic receptor antagonist (BB) poisoning follows similar principles. Significant myocardial depression, bradycardia and hypotension result in both cases. CCBs can also produce vasodilatory shock. Additionally, CCBs, such as verapamil and diltiazem, are commonly ingested in sustained-release formulations. This can also be the case for some BBs. Peak toxicity can be delayed by several hours. Provision of early gastrointestinal decontamination with activated charcoal and whole-bowel irrigation might mitigate this. Treatment of shock requires a multimodal approach to inotropic therapy that can be guided by echocardiographic or invasive haemodynamic assessment of myocardial function. High-dose insulin euglycaemia is commonly recommended as a first-line treatment in these poisonings, to improve myocardial contractility, and should be instituted early when myocardial dysfunction is suspected. Catecholamine infusions are complementary to this therapy for both inotropic and chronotropic support. Catecholamine vasopressors and vasopressin are used in the treatment of vasodilatory shock. Optimizing serum calcium concentration can confer some benefit to improving myocardial function and vascular tone after CCB poisoning. High-dose glucagon infusions have provided moderate chronotropic and inotropic benefits in BB poisoning. Phosphodiesterase inhibitors and levosimendan have positive inotropic effects but also produce peripheral vasodilation, which can limit blood pressure improvement. In cases of severe cardiogenic shock and/or cardiac arrest post-poisoning, extracorporeal cardiac assist devices have resulted in successful recovery. Other treatments used in refractory hypotension include intravenous lipid emulsion for lipophilic CCB and BB poisoning and methylene blue for refractory vasodilatory shock.


Assuntos
Antagonistas Adrenérgicos beta/intoxicação , Antídotos/uso terapêutico , Bloqueadores dos Canais de Cálcio/intoxicação , Overdose de Drogas/terapia , Bradicardia/induzido quimicamente , Bradicardia/tratamento farmacológico , Bradicardia/terapia , Overdose de Drogas/tratamento farmacológico , Humanos , Hipotensão/induzido quimicamente , Hipotensão/tratamento farmacológico , Hipotensão/terapia , Choque/induzido quimicamente , Choque/tratamento farmacológico , Choque/terapia
19.
Nutr Clin Pract ; 30(1): 104-10, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25516536

RESUMO

BACKGROUND: Thiamine plays a critical role in energy metabolism. Critically ill patients may have thiamine deficiency and increased mortality due to potentially irreversible consequences. The aim of this study was to show the impact of thiamine deficiency in a series of patients and the rapid response to thiamine replacement, showing the changes in clinical and metabolic conditions over time. METHODS: We described 3 cases of hospitalized patients who had received parenteral nutrition (PN) without vitamin supplementation. All the patients were admitted to the ICU between 2010 and 2011 with a severe form of lactic acidosis, an unstable circulatory state, and a different neurological disorder (a lethargic state, a severe form of impaired near-coma consciousness, and Wernicke encephalopathy). RESULTS: Intravenous (IV) administration of thiamine was associated with a rapid and marked restoration of acid-base balance, hemodynamic stability and the disappearance of neurological disturbances, and normalization of the clinical and biochemical conditions of all the patients within the following hours. CONCLUSIONS: The 3 cases demonstrated the rapidity of the reversal of severe thiamine deficiency, achieved by appropriate replacement in different hospitalized patients. The regression of clinical and biochemical disorders requires a prompt diagnosis and treatment based on the IV administration of thiamine and magnesium sulfate. In hospitalized patients at risk, thiamine deficiency is prevented by the integration of thiamine supplementation into PN and other forms of nutrition support.


Assuntos
Acidose Láctica/tratamento farmacológico , Estado Terminal/terapia , Nutrição Parenteral/efeitos adversos , Deficiência de Tiamina/tratamento farmacológico , Tiamina/administração & dosagem , Tiamina/uso terapêutico , Acidose Láctica/sangue , Acidose Láctica/etiologia , Administração Intravenosa , Adulto , Idoso , Feminino , Humanos , Doenças do Sistema Nervoso/sangue , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/etiologia , Nutrição Parenteral/métodos , Choque/sangue , Choque/tratamento farmacológico , Choque/etiologia , Deficiência de Tiamina/complicações , Deficiência de Tiamina/etiologia , Resultado do Tratamento
20.
Zhongguo Zhong Yao Za Zhi ; 38(18): 3104-9, 2013 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-24471336

RESUMO

Parenterally administered Shenmai has the functions of benefiting vital energy, nourishing Yin, generating body fluids, and activating the pulse. Modern pharmacological studies have shown that constituents of parenterally administered Shenmai such as ginsenosides and ophiopogonin can improve hypoxia tolerance, immunity, function, and microcirculation of the heart, and free radical scavenging. Therefore, parenterally administered Shenmai is a suitable treatment for shock. Literature review and analysis of HIS data outcomes, are the two methods used to study the type of shock treated, dose and combinations of other medications used with parenterally administered Shenmai. The results of the two methods are consistent in understanding the clinical features of shock therapy with parenterally administered Shenmai which thereby provides information for the design of prospective studies. However, the results of the two methods are limited by the poor quality of the literature and the low level of evidence for clinical evaluation after the registration of Shenmai. Nevertheless, HIS data provides retrospective data although some information is missing. Thus, although the results of the two methods can be used as the foundation to support the clinical evaluation of post-marketing parenterally administered Shenmai, final conclusions can only be drawn based on prospective studies.


Assuntos
Medicamentos de Ervas Chinesas/administração & dosagem , Sistemas de Informação Hospitalar/estatística & dados numéricos , Choque/tratamento farmacológico , Combinação de Medicamentos , Humanos , Infusões Parenterais , Ensaios Clínicos Pragmáticos como Assunto , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA